151 related articles for article (PubMed ID: 26677977)
21. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
22. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Yang YY; Huang YT; Lee TY; Chan CC; Yeh YC; Lee KC; Lin HC
Liver Transpl; 2012 Nov; 18(11):1371-83. PubMed ID: 22847887
[TBL] [Abstract][Full Text] [Related]
23. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
[TBL] [Abstract][Full Text] [Related]
24. Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Jin Y; Chen X; Gao Z; Shen X; Fu H; Pan Z; Yan H; Yang B; He Q; Xu Z; Luo P
Biomed Pharmacother; 2021 Dec; 144():112297. PubMed ID: 34649218
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
Lin JC; Huang WP; Liu CL; Lee JJ; Liu TP; Ko WC; Huang YC; Hsu ML; Wu CH; Chen YJ
Transplantation; 2013 Mar; 95(6):791-800. PubMed ID: 23354299
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
Zhu Y; Zhang X; Lou X; Chen M; Luo P; He Q
Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):659-667. PubMed ID: 29543385
[TBL] [Abstract][Full Text] [Related]
27. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.
Chanprapaph K; Rutnin S; Vachiramon V
Am J Clin Dermatol; 2016 Aug; 17(4):387-402. PubMed ID: 27221667
[TBL] [Abstract][Full Text] [Related]
28. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
29. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL
Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976
[TBL] [Abstract][Full Text] [Related]
30. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Sie M; den Dunnen WF; Lourens HJ; Meeuwsen-de Boer TG; Scherpen FJ; Zomerman WW; Kampen KR; Hoving EW; de Bont ES
PLoS One; 2015; 10(3):e0122555. PubMed ID: 25799134
[TBL] [Abstract][Full Text] [Related]
31. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
33. [¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Poot AJ; van der Wildt B; Stigter-van Walsum M; Rongen M; Schuit RC; Hendrikse NH; Eriksson J; van Dongen GA; Windhorst AD
Nucl Med Biol; 2013 May; 40(4):488-97. PubMed ID: 23522977
[TBL] [Abstract][Full Text] [Related]
34. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
35. Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20).
Schnabolk GW; Youngblood GL; Sweet DH
Am J Physiol Renal Physiol; 2006 Aug; 291(2):F314-21. PubMed ID: 16478971
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
37. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
40. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
